血液透析患者的肠内胆固醇吸收率高,从他汀类药物治疗抑制胆固醇合成中的受益低于其他病人群体。最近德国学者进行了一项随机对照研究,旨在探讨个人胆固醇吸收速率是否能够影响阿托伐他汀降低血液透析患者心血管疾病风险的效果。该因果分析包括的德国糖尿病透析研究项目1 030受试者,被随机分配到20mg的阿托伐他汀组(519例)和20 mg的安 Hemodialysis patients have high intestinal cholesterol absorption and benefit from statin therapy in cholesterol synthesis is lower than in other patient populations. Recently a German scholar conducted a randomized controlled study to investigate whether the rate of individual cholesterol absorption could affect the effect of atorvastatin on lowering the risk of cardiovascular disease in hemodialysis patients. This causal analysis included 1,030 subjects from the German Diabetes Dialysis Study, which were randomized to 20 mg of atorvastatin (519 patients) and 20 mg of